Biocryst Pharmaceuticals (BCRX) Accumulated Expenses (2011 - 2026)

Biocryst Pharmaceuticals has reported Accumulated Expenses for 16 years, with the latest figure at $119.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 28.89% year-over-year to $119.4 million; the trailing twelve-month figure through Mar 2026 stood at $119.4 million (up 28.89% YoY), and the FY2025 full-year result was $126.4 million, up 11.58% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $119.4 million, down from $126.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $126.4 million in Q4 2025, with the low at $63.6 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $93.0 million across 5 years, with a median of $89.6 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 94.33% — and 2023, when it retreated 5.53%.
• Biocryst Pharmaceuticals' Accumulated Expenses stood at $87.6 million in 2022, then gained by 17.49% to $102.9 million in 2023, then increased by 10.12% to $113.3 million in 2024, then gained by 11.58% to $126.4 million in 2025, then fell by 5.55% to $119.4 million in 2026.
• The last three Accumulated Expenses figures came in at $119.4 million (Q1 2026), $126.4 million (Q4 2025), and $118.8 million (Q3 2025), per Business Quant data.